MWM
ABCL icon

Mission Wealth Management’s AbCellera Biologics ABCL Stock Holding History

Mission Wealth Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20,000
Closed -$400K – 540
2021
Q3 		$400K Hold
20,000
– – 0.02% 340
2021
Q2 		$440K Buy
+20,000
New +$552K 0.02% 308

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mission Wealth Management's ABCL Position: Q1 2026 in Review

Mission Wealth Management sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 10,651 shares — an estimated $36.4K sold.

Mission Wealth Management first reported a position in ABCL in Q2 2021 and held it in 19 quarters. The position peaked at $674K in Q2 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Mission Wealth Management reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
  • Mission Wealth Management sold 10,651 AbCellera Biologics shares in Q1 2026, an estimated $36.4K.
  • Mission Wealth Management first reported a position in AbCellera Biologics in Q2 2021 and held it in 19 quarters.
  • Mission Wealth Management's AbCellera Biologics position peaked at $674K in Q2 2021.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Mission Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.